High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma

NCT02531841 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell-lymphoma

Interventions

DRUG: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
DRUG: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)

Sponsor

University Hospital Freiburg

Collaborators

[object Object]
[object Object]